Spago Nanomedical AB Company Description

Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden.

Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under preclinical development stage.

The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014.

The company was incorporated in 1999 and is based in Lund, Sweden.

Spago Nanomedical AB (publ)

Country	Sweden
Founded	1999
Industry	Biotechnology
Sector	Healthcare
Employees	13
CEO	Mats Hansen

Contact Details

Address: ScheelevAegen 22 Lund, 223 63 Sweden
Phone	46 4 68 11 88
Website	spagonanomedical.se

Stock Details

Ticker Symbol	SPAGO
Exchange	Nasdaq Stockholm
Share Class	Class B Shares
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0004899474
SIC Code	2836

Key Executives

Name	Position
Dr. Mats Hansen M.Sc., Ph.D.	Chief Executive Officer
Hanna Olsson M.Sc.	Chief Financial Officer
Paul Hargreaves	Chief Development Officer
Birgitta Rembratt Svensson	Head of CMC and Supply